ATE369385T1 - Neuer metabotropischer glutamat-rezeptor vom menschen - Google Patents

Neuer metabotropischer glutamat-rezeptor vom menschen

Info

Publication number
ATE369385T1
ATE369385T1 AT97933988T AT97933988T ATE369385T1 AT E369385 T1 ATE369385 T1 AT E369385T1 AT 97933988 T AT97933988 T AT 97933988T AT 97933988 T AT97933988 T AT 97933988T AT E369385 T1 ATE369385 T1 AT E369385T1
Authority
AT
Austria
Prior art keywords
metabotropic glutamate
glutamate receptor
mglur
human metabotropic
new human
Prior art date
Application number
AT97933988T
Other languages
English (en)
Inventor
Thomas Stormann
Rachel Simin
Lance Hammerland
Forrest Fuller
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Application granted granted Critical
Publication of ATE369385T1 publication Critical patent/ATE369385T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polyamides (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT97933988T 1996-02-21 1997-02-20 Neuer metabotropischer glutamat-rezeptor vom menschen ATE369385T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/604,298 US6084084A (en) 1996-02-21 1996-02-21 Human metabotropic glutamate receptor

Publications (1)

Publication Number Publication Date
ATE369385T1 true ATE369385T1 (de) 2007-08-15

Family

ID=24419059

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97933988T ATE369385T1 (de) 1996-02-21 1997-02-20 Neuer metabotropischer glutamat-rezeptor vom menschen

Country Status (10)

Country Link
US (3) US6084084A (de)
EP (1) EP0882065B1 (de)
JP (1) JP2000506392A (de)
AT (1) ATE369385T1 (de)
AU (1) AU719841B2 (de)
CA (1) CA2246751A1 (de)
DE (1) DE69737990T2 (de)
ES (1) ES2292193T3 (de)
IL (2) IL125711A0 (de)
WO (1) WO1997048724A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521297A (en) * 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
IL120424A0 (en) * 1995-07-26 1997-07-13 Nps Pharma Inc Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
US6221609B1 (en) * 1996-07-03 2001-04-24 Eli Lilly And Company Isolate nucleic acid encoding human MGLUR8
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
EP1066325A1 (de) * 1998-04-03 2001-01-10 Nps Pharmaceuticals, Inc. G-protein-gekoppelte rezeptoren und chimären gabab rezeptoren
EP1662255A3 (de) * 1998-08-18 2006-09-13 The Johns Hopkins University School Of Medicine Homer interagierende Proteine
WO2000011204A2 (en) * 1998-08-18 2000-03-02 The Johns Hopkins University School Of Medicine Homer interacting proteins
JP4714342B2 (ja) * 1998-08-31 2011-06-29 ザ プラヴアスト フエロウス アンド スカラース オブ ザ カレツヂ オブ ザ ハリー アンド アンデイヴアイデツド トリニテイ オブ クイーン エリザベス ニヤー ダブリン コアグラーゼ陰性スタフィロコカス菌に由来のポリペプチド及びポリヌクレオチド
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US6620850B2 (en) * 2001-09-19 2003-09-16 University Of Florida Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
CA2471198A1 (en) * 2001-12-20 2003-07-03 Merck & Co., Inc. Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
US7015195B2 (en) * 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
WO2004050858A2 (en) * 2002-12-04 2004-06-17 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
US20050186658A1 (en) * 2003-10-17 2005-08-25 Nps Pharmaceuticals, Inc. Chimeric metabotropic glutamate receptors and uses thereof
WO2005073730A1 (en) * 2004-01-31 2005-08-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human metabotropic glutamate receptor 8 (mglur8)
EP1805200B1 (de) * 2004-10-14 2012-01-04 Carnegie Institution Of Washington Neurotransmittersensoren und verfahren zu ihrer verwendung
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US8889950B2 (en) * 2006-07-28 2014-11-18 The George Washington University Repression of AtGLR3.2 increases plant biomass
US7424876B2 (en) * 2006-10-06 2008-09-16 Ford Global Technologies, Llc Pushrod engine with multiple independent lash adjusters for each pushrod
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
KR101520086B1 (ko) 2007-09-14 2015-05-14 얀센 파마슈티칼스 인코포레이티드 １´,３´-이치환된-４-페닐-３,４,５,６-테트라히드로-２ｈ,１´ｈ-[１,４´]비피리디닐-２´-온
WO2009079566A2 (en) * 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
WO2010011404A2 (en) * 2008-05-20 2010-01-28 Eos Neuroscience, Inc. Vectors for delivery of light-sensitive proteins and methods of use
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1012870B8 (pt) 2009-05-12 2021-05-25 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu uso como moduladores alostericos positivos de receptores de mglur2 e composição farmacêutica
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
PT2649069E (pt) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR102502485B1 (ko) 2014-01-21 2023-02-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
ME03518B (de) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinationen mit positiven allosterischen modulatoren von metabotropem glutamatergen rezeptor vom subtyp 2 und deren verwendung
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829583A (en) * 1971-02-20 1974-08-13 Hayashibara Ken Mixture of maltobionic acid and monosodium glutamate as a food seasoning
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5177011A (en) * 1988-08-18 1993-01-05 Calgene, Inc. Plant elongation factor promoters, coding sequences and uses
JP2944721B2 (ja) * 1990-08-22 1999-09-06 生化学工業株式会社 エンドトキシンの測定剤
NZ240921A (en) * 1990-12-12 1994-06-27 Zymogenetics Inc G protein coupled glutamate receptor (neurotransmitters), recombinant production
DE69233572T2 (de) * 1991-08-23 2006-08-31 NPS Pharmaceuticals, Inc., Salt Lake City Screening-Verfahren für Kalzium-Rezeptor aktive Verbindungen
DE69433714T2 (de) * 1991-08-23 2005-03-31 NPS Pharmaceuticals, Inc., Salt Lake City Kalzium - receptor aktive arylalkylamine
IL105587A0 (en) * 1992-05-08 1993-09-22 Lilly Co Eli Human metabotropic glutamate receptor and related dna compounds
WO1993023569A1 (en) * 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
JPH09503913A (ja) * 1993-09-20 1997-04-22 チバ−ガイギー アクチェンゲゼルシャフト ヒト代謝向性グルタミン酸受容体サブタイプ（ｈｍｒ４，ｈｍｒ６，ｈｍｒ７）および関連ｄｎａ化合物
US6274330B1 (en) * 1993-12-30 2001-08-14 Zymogenetics, Inc. L-AP4 sensitive glutamate receptors
AU6912594A (en) * 1994-05-16 1995-12-05 Human Genome Sciences, Inc. Neurotransmitter transporter
IL120424A0 (en) * 1995-07-26 1997-07-13 Nps Pharma Inc Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases

Also Published As

Publication number Publication date
WO1997048724A2 (en) 1997-12-24
JP2000506392A (ja) 2000-05-30
AU719841B2 (en) 2000-05-18
ES2292193T3 (es) 2008-03-01
AU3715697A (en) 1998-01-07
EP0882065A2 (de) 1998-12-09
CA2246751A1 (en) 1997-12-24
US6051688A (en) 2000-04-18
WO1997048724A3 (en) 1998-03-26
IL125711A0 (en) 1999-04-11
EP0882065B1 (de) 2007-08-08
DE69737990D1 (de) 2007-09-20
US6084084A (en) 2000-07-04
US6077675A (en) 2000-06-20
DE69737990T2 (de) 2008-09-11
IL125711A (en) 2006-09-05

Similar Documents

Publication Publication Date Title
ATE369385T1 (de) Neuer metabotropischer glutamat-rezeptor vom menschen
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
CY1113355T1 (el) Χρηση θεραπειας νευροτοξινης για θεραπευτικη αγωγη ουρολογικων και σχετικων διαταραχων
DE69625691T2 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
NO20000396L (no) Katalytiske monoklonale antistoffer med protease-aktivitet for selektiv lysis av proteinkomponenten hos plakker og aggregater relatert til patologiske tilstander
NO985975L (no) Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
DE69738613D1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE500328T1 (de) Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
ES2063060T3 (es) Benzamida contra enfermedades cognoscitivas.
ATE135916T1 (de) Hirnaktivitätfördernde zubereitungen
ATE331531T1 (de) Lösliche lymphotoxin-beta rezeptoren, anti- lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
ES2068388T3 (es) Moleculas de receptor de hormona de la glucoproteina.
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
FR2569697B1 (fr) Produits derives de la mitomycine et leur application au traitement de maladies neoplasiques
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
ATE216589T1 (de) Neurotoxine zur behandlung von hauterkrankungen bei säugetieren
NO994630D0 (no) Metoder for behandling av vaskulaere sykdommer
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
MX9206339A (es) Nueva proteina inhibidora de trombina a partir de chinches de monte
ATE249837T1 (de) Caspase 8-inhibitoren zur immunsuppression
CA2217463A1 (fr) Utilisation de la sulbutiamine pour l'obtention de compositions pharmaceutiques utiles dans le traitement de certains troubles psychomoteurs et psycho-intellectuels
EP0177826A3 (de) Arzneimittel und Diagnostikum mit Wachstumshormon-Releasingfaktor-Wirkung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties